HPV vaccination in boys and men

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 2106-2108

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anal cancer; Cost effectiveness; HPV; Men; Tonsillar cancer; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ANUS NEOPLASMS; COMPLICATION; CONDYLOMATA ACUMINATA; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; HUMAN; IMMUNOLOGY; MALE; PAPILLOMAVIRUS INFECTIONS; UTILIZATION; VACCINATION; ALCOHOLISM; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; INCIDENCE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; ORAL SEX; PREVALENCE; REVIEW; RISK FACTOR; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; SQUAMOUS CELL CARCINOMA; TOBACCO USE; UTERINE CERVIX CANCER; WART VIRUS;

ANUS NEOPLASMS; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84908407295     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29138     Document Type: Review

References (33)

1. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(Suppl 5):F55-70; PMID:23199966; http://dx.doi.org/10.1016/j.vaccine.2012.06.083
2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5):F12-23; PMID:23199955; http://dx.doi.org/10.1016/j.vaccine.2012.07.055
3. Quinn MA. Cervical screening in the 21st century. J Med Assoc Thai 2004; 87(Suppl 3):S94-5; PMID:21213500
4. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30(Suppl 5):F24-33; PMID:23199964; http://dx.doi.org/10.1016/j.vaccine.2012.05.089
5. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124:2375-83; PMID:19189402; http://dx.doi.org/10.1002/ijc.24215
6. Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer 2006; 95:87-90; PMID:16721368; http://dx.doi.org/10.1038/sj.bjc.6603175
7. Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30(Suppl 5):F168-74; PMID:23199960; http://dx.doi.org/10.1016/j.vaccine.2012.06.045
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
9. Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Fabiánová E, Rudnai P, Brennan P. Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol 2007; 165:814-20; PMID:17244634; http://dx.doi.org/10.1093/aje/kwk066
10. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11:781-9; PMID:20451455; http://dx.doi.org/10.1016/S1470-2045(10)70017-6
11. Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O'Brien CJ, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010; 28:3269-72; PMID:20226244; http://dx.doi.org/10.1016/j.vaccine.2010.02.098
12. Chaturvedi AK. Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers. Head Neck Pathol 2012; 6(Suppl 1):16-24; PMID:21984020; http://dx.doi.org/10.1007/s12105-012-0377-0
13. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100:407-20; PMID:18334711; http://dx.doi.org/10.1093/jnci/djn025
14. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301; PMID:21969503; http://dx.doi.org/10.1200/JCO.2011.36.4596
15. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91:942-53; PMID:15292939
16. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43; PMID:18708396; http://dx.doi.org/10.1158/1055-9965.EPI-08-0151
17. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377:932-40; PMID:21367446; http://dx.doi.org/10.1016/S0140-6736(10)62342-2
18. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174:927-36; PMID:8896492; http://dx.doi.org/10.1093/infdis/174.5.927
19. Edelstein ZR, Carter JJ, Garg R, Winer RL, Feng Q, Galloway DA, Koutsky LA. Serum antibody response following genital α9 human papillomavirus infection in young men. J Infect Dis 2011; 204:209-16; PMID:21673030; http://dx.doi.org/10.1093/infdis/jir242
20. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298; http://dx.doi.org/10.1136/bmj.f2032
21. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
22. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
23. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012; 19:261-7; PMID:22155768; http://dx.doi.org/10.1128/CVI.05208-11
24. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-11; PMID:21288094; http://dx.doi.org/10.1056/NEJMoa0909537
25. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
26. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769; PMID:18640957; http://dx.doi.org/10.1136/bmj.a769
27. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(Suppl 1):S97-106; PMID:15627236; http://dx.doi.org/10.1086/425271
28. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30(Suppl 5):F157-67; PMID:23199959; http://dx.doi.org/10.1016/j.vaccine.2012.06.091
29. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7; PMID:21970896; http://dx.doi.org/10.1136/sextrans-2011-050234
30. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40:130-5; PMID:23324976
31. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705-8; PMID:22189893
32. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, et al.; Authors of the ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31(Suppl 8):I1-31; PMID:24229716; http://dx.doi.org/10.1016/j.vaccine.2013.07.026
33. Korostil IA, Ali H, Guy RJ, Donovan B, Law MG, Regan DG. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013; 40:833-5; PMID:24113401; http://dx.doi.org/10.1097/OLQ.0000000000000030